loader2
Partner With Us NRI

Hester Biosciences Ltd share Price Today

Company details

1,603.60
1,637.10
1,292.85
1,939.95
6M Return -2.63%
1Y Return -10.26%
Mkt Cap.(Cr) 1,389.11
Volume 5,591
Div Yield 0.49%
OI
-
OI Chg %
-
Volume 5,591
NSE

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Animal health drives sales as poultry decline continues
About The Stock

    Hester is one of India’s leading animal healthcare companies & the second largest poultry vaccine manufacturer in the country. It has a strategic presence in 30+ countries with key markets being India, Nepal and Tanzania.

    • It operates through four broad verticals: poultry vaccines, poultry health products, animal vaccines and animal health products
    • Sales break-up for Q3FY23: Poultry healthcare: 42%, Animal healthcare: 58%
Q3FY23

    Animal healthcare boosted revenues, gross margins impacted due to stock write off.

    • Sales were up 34.6% YoY to ₹ 75 crore
    • EBITDA was at ₹ 19 crore, up 24.9%, with margins at 25%
    • Adjusted PAT was at ₹ 12.3 crore (up 45% YoY)

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Hester Biosciences announced Q2FY24 & H1FY24 results:

1. Financial Performance:

  • Q2FY24:
    • Revenue from Operations: Rs 704.55 crore, down 4% YoY
    • EBITDA: Rs 132.12 crore, up 4% YoY
    • Profit after Tax (excl. OCI): Rs 40.41 crore, down 39% YoY
    • Earnings Per Share (EPS): Rs 4.75, down 39% YoY
  • H1FY24:
    • Revenue from Operations: Rs 1,583.08 crore, up 28% YoY
    • EBITDA: Rs 275.75 crore, up 37% YoY
    • Profit after Tax (excl. OCI): Rs 107.51 crore, up 6% YoY
    • Earnings Per Share (EPS): Rs 12.64, up 6% YoY

2. Division Performance:
-  Animal Healthcare division experienced a 16% decline in sales in Q2FY24 due to uneven sales of the Goat Pox Vaccine.
- Poultry Healthcare division saw a 4% decrease in overall sales in Q2FY24, with a growth in domestic vaccine sales, but a reduction in export sales.
- Petcare division achieved impressive performance, growing 98% in Q2FY24.

3. Subsidiary Performance:
- Hester Nepal had a turnover of Rs 7.28 million in Q2FY24, primarily from domestic sales of vaccines, with an overall net loss of Rs 7.05 million.
- Hester Africa continued export sales but faced an overall loss of Rs 49.17 million due to foreign exchange fluctuations.
- Hester's share of profit in the joint venture entity, Thrishool Exim Limited (Tanzania), increased by 9.86 million in Q2FY24.

 

 

Result PDF

View Other Company Results

Hester Biosciences Ltd shares SWOT Analysis

Strengths (4)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Book Value per share Improving for last 2 years
  • Company with Zero Promoter Pledge

Weakness (10)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years
  • Decline in Net Profit (QoQ)

Opportunity (1)

  • RSI indicating price strength

Threats (2)

  • Companies with growing costs YoY for long term projects
  • High PE (PE > 40)
Discover More

Resistance and support

R1 1,645.5
R2 1,658.0
R3 1,679.0
Pivot

1,624.53

S1 1,612.0
S2 1,591.0
S3 1,578.5
EMA SMA
1,543.7
1,491.8
1,502.7
1,569.7
1,522.0
1,447.7
1,474.3
1,581.1
Delivery and volume
Discover More
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
RAJIV DINESH GANDHI Bulk Purchase 2017-03-22 732.1 90000 BSE
HESTER COATINGS PRIVATE LIMITED Bulk Sell 2017-03-22 732.1 90000 BSE
RAJIV DINESH GANDHI Block Purchase 2017-03-22 732.1 90000 BSE
Discover More
Name Category Shares
Rajiv Dinesh Gandhi PROMOTER 10.47%
Sanjiv Dinesh Gandhi PROMOTER 8.2%
Nina Rajiv Gandhi PROMOTER 8.19%
Shaila Bhupendra Gandhi PROMOTER 5.78%
Bhupendra Vithaldas Gandhi PROMOTER 4.69%
Anup Chandravadan Kapadia PROMOTER 2.68%
Biolink Healthcare Limited PROMOTER 2.93%
Hester Coatings LLP PROMOTER 0.75%
Ravin Gandhi PROMOTER 4.74%
Bela Gandhi PROMOTER 4.71%

OUR RESEARCH VIEW

Investment recommendation
Animal health drives sales as poultry decline continues
Call Date
02 Feb 2023
Entry Price 1,790.00
Target Price 1,830.00
Duration
12-18 Month
HOLD View Report
DISCOVER MORE

FINANCIALS

Sales
Operating Profit
Profit after Tax
DISCOVER MORE
Equity
Reserves and Surplus
Debt
DISCOVER MORE
Sales
Operating Profit
Profit after Tax
DISCOVER MORE
PE
Debt/Equity
P BV
DISCOVER MORE

Hester Biosciences Ltd Stocks COMPARISON

Financials( ₹ in Cr) Hester Biosciences Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Divis Laboratories Ltd
Price 1,632.90 1,522.80 1,345.75 5,942.85 3,671.70
% Change 0.69 0.42 -0.12 -0.24 -1
Mcap ₹ Cr 1,389.11 365,370.73 108,649.13 99,132.09 97,472.25
Revenue TTM ₹ Cr 266.09 43,885.68 15,790.60 24,669.70 7,767.51
Net Profit TTM ₹ Cr 28.04 8,560.84 2,513.47 4,507.30 1,823.38
PE TTM 74.83 38.80 27.51 19.01 71.35
1 Year Return -10.26 51.55 45.60 20.98 12.26
ROCE 9.01 16.79 14.76 25.99 19.30
ROE 10.39 16.46 10.66 21.21 14.89
DISCOVER MORE
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 279.73 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 24,289.49 -9,580.22
LAST 3M 82,644.28 34,986.47
LAST 6M 142,142.07 66,572.41
LAST 12M 216,755.16 194,314.28

Hester Biosciences Ltd Information

Stock PE (TTM)
74.83
Promoter Holding
53.73%
Book Value
331.4087
ROCE
9.01%
ROE
10.39%
Description

  • Incorporated as a private limited company in Apr.`87, Hester Pharmaceutical (HPL) was converted into a public limited company in Nov.`93. HPL markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents. It markets the veterinary products of many international companies including Ghen Corporation, Japan; Maine Biological Laboratories, US; Idexx Corporation, US; International Diagnostic Systems Corporation, US; Biogal Galed Laboratories, Israel; and Kemin Europa, Belgium. The company`s own production of veterinary vaccines (in Vials) is expected to commence soon. HPL has technical collaborations with Maine Biological Laboratories and Ghen Corporation. During 1996-97, company successfully implemented veterinary vaccine and commercial production has begun. The company has received licenses for producing 10 additional poultry vaccines.It has also signed an manufacturing agreement with Sinsui Inc for producing poultry vaccines.

Read More
Registered Address

1st Flr PushpakPachvati Circle, Motilal Hirabhai Road, Ahmedabad, Gujarat, 380006

Tel : 91-079-26445107
Email : investor:hesterbiosciences.co.in
Website : http://www.hester.in
Registrar

Sharepro Services India Pvt Lt

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524669
NSE Code : HESTERBIO
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE782E01017

FAQ’s on Hester Biosciences Ltd Shares

You can buy Hester Biosciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Hester Biosciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Apr 19, 2024 03:40 PM the closing price of Hester Biosciences Ltd was ₹ 1,632.90.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Apr 19, 2024 03:40 PM, the market cap of Hester Biosciences Ltd stood at ₹ 1,389.11.

The latest PE ratio of Hester Biosciences Ltd as of Apr 19, 2024 03:40 PM is 74.83

The latest PB ratio of Hester Biosciences Ltd as of Apr 19, 2024 03:40 PM is 0.20

The 52-week high of Hester Biosciences Ltd share price is ₹ 1,939.95 while the 52-week low is ₹ 1,292.85

According to analyst recommendations, Hester Biosciences Ltd Share has a “Buy” rating for the long term.

Download Our

Download App
market app